• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Host candidate gene polymorphisms and clearance of drug-resistant Plasmodium falciparum parasites.

机构信息

Malaria Research and Training Centre, Faculty of Medicine, Pharmacy and Odontostomatology, University of Bamako, Mali.

出版信息

Malar J. 2011 Aug 25;10:250. doi: 10.1186/1475-2875-10-250.

DOI:10.1186/1475-2875-10-250
PMID:21867552
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3177816/
Abstract

BACKGROUND

Resistance to anti-malarial drugs is a widespread problem for control programmes for this devastating disease. Molecular tests are available for many anti-malarial drugs and are useful tools for the surveillance of drug resistance. However, the correlation of treatment outcome and molecular tests with particular parasite markers is not perfect, due in part to individuals who are able to clear genotypically drug-resistant parasites. This study aimed to identify molecular markers in the human genome that correlate with the clearance of malaria parasites after drug treatment, despite the drug resistance profile of the protozoan as predicted by molecular approaches.

METHODS

3721 samples from five African countries, which were known to contain genotypically drug resistant parasites, were analysed. These parasites were collected from patients who subsequently failed to clear their infection following drug treatment, as expected, but also from patients who successfully cleared their infections with drug-resistant parasites. 67 human polymorphisms (SNPs) on 17 chromosomes were analysed using Sequenom's mass spectrometry iPLEX gold platform, to identify regions of the human genome, which contribute to enhanced clearance of drug resistant parasites.

RESULTS

An analysis of all data from the five countries revealed significant associations between the phenotype of ability to clear drug-resistant Plasmodium falciparum infection and human immune response loci common to all populations. Overall, three SNPs showed a significant association with clearance of drug-resistant parasites with odds ratios of 0.76 for SNP rs2706384 (95% CI 0.71-0.92, P = 0.005), 0.66 for SNP rs1805015 (95% CI 0.45-0.97, P = 0.03), and 0.67 for SNP rs1128127 (95% CI 0.45-0.99, P = 0.05), after adjustment for possible confounding factors. The first two SNPs (rs2706384 and rs1805015) are within loci involved in pro-inflammatory (interferon-gamma) and anti-inflammatory (IL-4) cytokine responses. The third locus encodes a protein involved in the degradation of misfolded proteins within the endoplasmic reticulum, and its role, if any, in the clearance phenotype is unclear.

CONCLUSIONS

The study showed significant association of three loci in the human genome with the ability of parasite to clear drug-resistant P. falciparum in samples taken from five countries distributed across sub-Saharan Africa. Both SNP rs2706384 and SNP1805015 have previously been reported to be associated with risk of malaria infection in African populations. The loci are involved in the Th1/Th2 balance, and the association of SNPs within these genes suggests a key role for antibody in the clearance of drug-resistant parasites. It is possible that patients able to clear drug-resistant infections have an enhanced ability to control parasite growth.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/104c/3177816/863600770b4b/1475-2875-10-250-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/104c/3177816/863600770b4b/1475-2875-10-250-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/104c/3177816/863600770b4b/1475-2875-10-250-1.jpg

相似文献

1
Host candidate gene polymorphisms and clearance of drug-resistant Plasmodium falciparum parasites.宿主候选基因多态性与耐药性疟原虫清除。
Malar J. 2011 Aug 25;10:250. doi: 10.1186/1475-2875-10-250.
2
Host candidate gene polymorphisms and associated clearance of P. falciparum amodiaquine and fansidar resistance mutants in children less than 5 years in Cameroon.喀麦隆5岁以下儿童中宿主候选基因多态性与恶性疟原虫阿莫地喹清除及Fansidar耐药突变体的相关性
Pathog Glob Health. 2014 Oct;108(7):323-33. doi: 10.1179/2047773214Y.0000000159. Epub 2014 Nov 12.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
Drug resistance profile and clonality of Plasmodium falciparum parasites in Cape Verde: the 2017 malaria outbreak.佛得角恶性疟原虫寄生虫的耐药谱和克隆性:2017 年疟疾疫情。
Malar J. 2021 Mar 31;20(1):172. doi: 10.1186/s12936-021-03708-z.
5
Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study.柬埔寨西部磅士卑省的青蒿素耐药疟原虫:寄生虫清除率研究。
Lancet Infect Dis. 2012 Nov;12(11):851-8. doi: 10.1016/S1473-3099(12)70181-0. Epub 2012 Aug 30.
6
Culture-adapted Plasmodium falciparum isolates from UK travellers: in vitro drug sensitivity, clonality and drug resistance markers.从英国旅行者中分离出的具有文化适应性的恶性疟原虫:体外药物敏感性、克隆性和耐药性标志物。
Malar J. 2013 Sep 13;12:320. doi: 10.1186/1475-2875-12-320.
7
Factors contributing to delay in parasite clearance in uncomplicated falciparum malaria in children.导致儿童无并发症恶性疟原虫疟疾寄生虫清除延迟的因素。
Malar J. 2010 Feb 15;9:53. doi: 10.1186/1475-2875-9-53.
8
Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study.撒哈拉以南非洲地区恶性疟原虫中假定青蒿素抗性突变的缺失:一项分子流行病学研究。
J Infect Dis. 2015 Mar 1;211(5):680-8. doi: 10.1093/infdis/jiu467. Epub 2014 Sep 1.
9
Prevalence of mutations in Plasmodium falciparum genes associated with resistance to different antimalarial drugs in Nyando, Kisumu County in Kenya.肯尼亚基苏木县尼亚永地区与不同抗疟药物耐药性相关的疟原虫基因突变流行情况。
Infect Genet Evol. 2020 Mar;78:104121. doi: 10.1016/j.meegid.2019.104121. Epub 2019 Nov 19.
10
Field-based evidence of fast and global increase of Plasmodium falciparum drug-resistance by DNA-microarrays and PCR/RFLP in Niger.通过DNA微阵列和PCR/RFLP技术在尼日尔获得的关于恶性疟原虫耐药性迅速全球增加的实地证据。
Malar J. 2009 Feb 23;8:32. doi: 10.1186/1475-2875-8-32.

引用本文的文献

1
Low Complexity of Infection Is Associated With Molecular Persistence of in Kenya and Tanzania.感染的低复杂性与肯尼亚和坦桑尼亚的分子持续性相关。
Front Epidemiol. 2022 Jun 6;2:852237. doi: 10.3389/fepid.2022.852237. eCollection 2022.
2
Risk score prediction model based on single nucleotide polymorphism for predicting malaria: a machine learning approach.基于单核苷酸多态性的疟疾风险评分预测模型:一种机器学习方法。
BMC Bioinformatics. 2022 Aug 7;23(1):325. doi: 10.1186/s12859-022-04870-0.
3
Leveraging Mann-Whitney U test on large-scale genetic variation data for analysing malaria genetic markers.

本文引用的文献

1
Candidate malaria susceptibility/protective SNPs in hospital and population-based studies: the effect of sub-structuring.基于医院和人群的研究中的候选疟疾易感性/保护性单核苷酸多态性:亚结构的影响。
Malar J. 2010 May 8;9:119. doi: 10.1186/1475-2875-9-119.
2
Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria.宿主免疫作为恶性疟原虫疟疾治疗结果的决定因素。
Lancet Infect Dis. 2010 Jan;10(1):51-9. doi: 10.1016/S1473-3099(09)70322-6.
3
Efficacy of amodiaquine, sulphadoxine-pyrimethamine and their combination for the treatment of uncomplicated Plasmodium falciparum malaria in children in Cameroon at the time of policy change to artemisinin-based combination therapy.
利用大规模遗传变异数据的曼-惠特尼 U 检验分析疟疾遗传标记。
Malar J. 2022 Mar 9;21(1):79. doi: 10.1186/s12936-022-04104-x.
4
Drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon: a systematic review and meta-analysis (1998-2020).抗疟药在喀麦隆疗效演变中的耐药标志物:系统评价和荟萃分析(1998-2020 年)。
Malar J. 2021 Jan 9;20(1):32. doi: 10.1186/s12936-020-03543-8.
5
Geographical distribution of complement receptor type 1 variants and their associated disease risk.1型补体受体变体的地理分布及其相关疾病风险。
PLoS One. 2017 May 17;12(5):e0175973. doi: 10.1371/journal.pone.0175973. eCollection 2017.
在喀麦隆基于青蒿素的联合疗法政策改变时,评价阿莫地喹、磺胺多辛-乙胺嘧啶及其联合疗法治疗儿童无并发症恶性疟原虫疟疾的疗效。
Malar J. 2010 Jan 27;9:34. doi: 10.1186/1475-2875-9-34.
4
A molecular map of chloroquine resistance in Mali.马里氯喹抗性的分子图谱。
FEMS Immunol Med Microbiol. 2010 Feb;58(1):113-8. doi: 10.1111/j.1574-695X.2009.00641.x. Epub 2009 Nov 2.
5
Pharmacogenetics of antimalarial drugs: effect on metabolism and transport.抗疟药物的药物遗传学:对代谢和转运的影响。
Lancet Infect Dis. 2009 Dec;9(12):760-74. doi: 10.1016/S1473-3099(09)70320-2.
6
Genome-wide comparisons of variation in linkage disequilibrium.连锁不平衡中变异的全基因组比较。
Genome Res. 2009 Oct;19(10):1849-60. doi: 10.1101/gr.092189.109. Epub 2009 Jun 18.
7
Genetics of susceptibility to Plasmodium falciparum: from classical malaria resistance genes towards genome-wide association studies.恶性疟原虫易感性的遗传学:从经典疟疾抗性基因到全基因组关联研究
Parasite Immunol. 2009 May;31(5):234-53. doi: 10.1111/j.1365-3024.2009.01106.x.
8
Acquired immunity to malaria.获得性疟疾免疫力。
Clin Microbiol Rev. 2009 Jan;22(1):13-36, Table of Contents. doi: 10.1128/CMR.00025-08.
9
A genetic association study in the Gambia using tagging polymorphisms in the major histocompatibility complex class III region implicates a HLA-B associated transcript 2 polymorphism in severe malaria susceptibility.在冈比亚开展的一项基因关联研究,利用主要组织相容性复合体III类区域中的标签多态性,发现一种与HLA - B相关转录本2的多态性与严重疟疾易感性有关。
Hum Genet. 2009 Feb;125(1):105-9. doi: 10.1007/s00439-008-0597-2. Epub 2008 Nov 28.
10
Interferon regulatory factor-1 polymorphisms are associated with the control of Plasmodium falciparum infection.干扰素调节因子-1基因多态性与恶性疟原虫感染的控制相关。
Genes Immun. 2008 Mar;9(2):122-9. doi: 10.1038/sj.gene.6364456. Epub 2008 Jan 17.